Ketamine for Acute Ischemic Stroke
This study is testing if intravenous (IV) ketamine can help protect the brain after an acute ischemic stroke. Researchers believe ketamine might reduce "neuroexcitotoxicity," which is when brain cells are overstimulated and damaged after a stroke. You could be eligible if you are 18 or older, have had an acute ischemic stroke within 24 hours, and have MRI evidence of the stroke. The main goal is to see if ketamine improves your recovery and daily function, measured by a score called the modified Rankin scale, 90 days after your stroke. The current recruitment status is unclear.
- Study design
- This is an interventional study planning to enroll 120 participants. It compares ketamine infusion to a placebo (normal saline) infusion.
- What's involved
- If you join, you would receive an IV infusion for 24 hours while admitted to the hospital. You would also receive Midazolam injections every 4 hours and have blood ketamine levels measured daily.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your recovery will be assessed on day 1 and again 90 days after your stroke.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Quelling of Excitotoxicity in Acute Stroke With Ketamine
At a glance
Conditions
NCT03223220
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Lankenau Medical Center
Wynnewood, Pennsylvaniastudy coordinator listed
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Change in weighted modified Rankin scale score between day 1 and 90 will be assessed.On day 1 and at 90 days
An improvement of 2 in mRS score will be considered favorable outcome.